Take Solutions
NSE: TAKE · Healthcare Research, Analytics & Technology
Snapshot
Unlock Take Solutions's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
TAKE Solutions provides domain-intensive technology and consulting services primarily focused on the life sciences and supply chain management sectors. The company supports biopharmaceutical and medical device firms through clinical research, regulatory affairs, pharmacovigilance, and data science solutions.
Business Model
The company generates revenue through IP-driven technology solutions, functional consulting services, and outsourced clinical research support. It serves a diverse client base ranging from large innovator biopharmaceutical companies to generics manufacturers.
Growth Outlook
Growth is driven by the increasing demand for outsourced clinical research and regulatory compliance services within the global life sciences industry. The company continues to leverage its expertise in data sciences and pharmacovigilance to capture market share among innovator and generics manufacturers.
Key Risks
- Regulatory Compliance Risk. Failure to adhere to stringent global clinical and regulatory standards could result in loss of business and reputational damage.
- Client Concentration. The company's reliance on a specific set of biopharmaceutical and device clients makes it vulnerable to shifts in their R&D spending priorities.
- Geopolitical and Currency Risk. Operating across the US, Europe, and Asia Pacific exposes the company to fluctuations in foreign exchange rates and international trade policies.
- Technological Obsolescence. Rapid advancements in life sciences technology require continuous investment to maintain the relevance of the company's IP-driven solutions.
Start your research today
Unlock AI insights, financials, peers and live data on Take Solutions and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹13 Cr
TTM · consolidated
EPS
₹0.86
TTM · consolidated
RETURN ON EQUITY
49.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
24.2%
TTM · consolidated
P/E
14.7×
Q1 FY27 · consolidated
EV/EBITDA
37.6x
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Take SolutionsTAKE | ₹235 Cr | 14.7× | 37.62 | — | 7.4% | 49.8% | 24.2% | +4.9% |
Syngene International Ltd.SYNGENE | ₹15,414 Cr | 65.7× | 17.24 | -3.4% | 24.5% | 4.6% | 6.2% | -42.8% |
Indegene Ltd.INDGN | ₹14,419 Cr | 35.5× | 19.70 | 30.4% | 18.8% | 13.9% | 17.4% | +4.9% |
Suven Life Sciences LimitedSUVEN | ₹9,659 Cr | -20.7× | -27.94 | 17.3% | -557.4% | -100.5% | -99.8% | +48.9% |
Vimta LabsVIMTALABS | ₹2,728 Cr | 32.7× | 17.34 | 15.2% | 37.3% | 19.1% | 24.1% | -18.3% |
Fabtech Technologies LimitedFABTECH | ₹661 Cr | 10.3× | 9.04 | — | 16.3% | 11.6% | 14.1% | — |
As of Q1 FY27
Financials
Take Solutions
NSE: TAKE · Healthcare Research, Analytics & Technology
Snapshot
Unlock Take Solutions's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
TAKE Solutions provides domain-intensive technology and consulting services primarily focused on the life sciences and supply chain management sectors. The company supports biopharmaceutical and medical device firms through clinical research, regulatory affairs, pharmacovigilance, and data science solutions.
Business Model
The company generates revenue through IP-driven technology solutions, functional consulting services, and outsourced clinical research support. It serves a diverse client base ranging from large innovator biopharmaceutical companies to generics manufacturers.
Growth Outlook
Growth is driven by the increasing demand for outsourced clinical research and regulatory compliance services within the global life sciences industry. The company continues to leverage its expertise in data sciences and pharmacovigilance to capture market share among innovator and generics manufacturers.
Key Risks
- Regulatory Compliance Risk. Failure to adhere to stringent global clinical and regulatory standards could result in loss of business and reputational damage.
- Client Concentration. The company's reliance on a specific set of biopharmaceutical and device clients makes it vulnerable to shifts in their R&D spending priorities.
- Geopolitical and Currency Risk. Operating across the US, Europe, and Asia Pacific exposes the company to fluctuations in foreign exchange rates and international trade policies.
- Technological Obsolescence. Rapid advancements in life sciences technology require continuous investment to maintain the relevance of the company's IP-driven solutions.
Start your research today
Unlock AI insights, financials, peers and live data on Take Solutions and 5,000+ companies — free.
Key Metrics
NET PROFIT
₹13 Cr
TTM · consolidated
EPS
₹0.86
TTM · consolidated
RETURN ON EQUITY
49.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
24.2%
TTM · consolidated
P/E
14.7x
Q1 FY27 · consolidated
EV/EBITDA
37.6x
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q1 FY27